Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Y-39983. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 known ✓ | O75116 | 7/20 | 1.00 |
| ▸ | ROCK1 known ✓ | Q13464 | 5/20 | 0.98 |
| ▸ | CIT | O14578 | 10/20 | 0.98 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.98 |
| ▸ | PRKACA | P17612 | 2/20 | 0.98 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.98 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.98 |
| ▸ | PKN2 | Q16513 | 2/20 | 0.98 |
| ▸ | PRKD2 | Q9BZL6 | 2/20 | 0.98 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.98 |
| ▸ | PRKCB | P05771 | 1/20 | 0.98 |
| ▸ | PRKCA | P17252 | 1/20 | 0.98 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.98 |
| ▸ | MARK3 | P27448 | 1/20 | 0.98 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.98 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.98 |
| ▸ | CLK1 | P49759 | 1/20 | 0.98 |
| ▸ | GSK3A | P49840 | 1/20 | 0.98 |
| ▸ | GSK3B | P49841 | 1/20 | 0.98 |
| ▸ | CDK9 | P50750 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Y-39983 SCHEMBL599800 | 1.00 | ROCK2 (1.00) | ROCK2CITROCK1PRKD3PRKACA | |
| Y-39983 SCHEMBL1927761 | 1.00 | ROCK2 (1.00) | ROCK2CITROCK1PRKD3PRKACA | |
| Y-39983 SCHEMBL1927760 | 1.00 | ROCK2 (1.00) | ROCK2CITROCK1PRKD3PRKACA | |
| Y-39983 SCHEMBL29816387 | 1.00 | ROCK2 (1.00) | ROCK2CITROCK1PRKD3PRKACA | |
| Y-39983 SCHEMBL29666940 | 1.00 | ROCK2 (1.00) | ROCK2CITROCK1PRKD3PRKACA | |
| Y-39983 SCHEMBL15006545 | 0.99 | ROCK2 (0.98) | ROCK2CITROCK1PRKD3PRKACA | |
| Y-39983 SCHEMBL15006546 | 0.99 | ROCK2 (0.98) | ROCK2CITROCK1PRKD3PRKACA | |
| Y-39983 SCHEMBL29431274 | 0.99 | CIT (1.00) | ROCK2CITROCK1PRKD3PRKACA | |
| Y-39983 SCHEMBL25685649 | 0.99 | CIT (1.00) | ROCK2CITROCK1PRKD3PRKACA | |
| Y-39983 SCHEMBL29893202 | 0.99 | CIT (1.00) | ROCK2CITROCK1PRKD3PRKACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100041671-A1 | Methods for treating glaucoma | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-02-18 | — | — | US | claimed |
| US-20260028584-A1 | METHOD FOR EVALUATING AGGREGATION-SUPPRESSING ACTIVITY OR AGGREGATION-PROMOTING ACTIVITY ON AGGREGATING PROTEIN USING ORGANOID, AND METHOD FOR PRODUCING ORGANOID | KANEKA CORPORATION (JP) | 2026-01-29 | — | — | US | disclosed |
| WO-2025058089-A1 | AGENT FOR SUPPRESSING AMYLOID β AGGREGATION/DEPOSITION AND AGENT FOR SUPPRESSING/IMPROVING COGNITIVE DECLINE OF SUBJECT | 株式会社カネカ | 2025-03-20 | — | — | WO | disclosed |
| WO-2024071361-A1 | METHOD FOR ASSESSING COAGULATION INHIBITION ACTIVITY OR COAGULATION PROMOTION ACTIVITY AGAINST COAGULATIVE PROTEIN | 株式会社カネカ | 2024-04-04 | — | — | WO | disclosed |
| WO-2022045342-A1 | FACIAL NERVE PARALYSIS TREATMENT COMPOSITION | 欠畑 誠治 | 2022-03-03 | — | — | WO | disclosed |
| US-20210062159-A1 | CELL AGGREGATION PROMOTER | KANEKA CORPORATION (JP) | 2021-03-04 | — | — | US | disclosed |
| EP-3733837-A1 | CELL AGGREGATION PROMOTING AGENT | Kaneka Corporation (JP) | 2020-11-04 | — | — | EP | disclosed |
| EP-1568382-B1 | REMEDY FOR GLAUCOMA COMPRISING Rho KINASE INHIBITOR AND beta-BLOCKER | SANTEN PHARMACEUTICAL CO LTD (JP) | 2013-11-06 | — | — | EP | disclosed |
| EP-1541151-B1 | REMEDY FOR GLAUCOMA COMPRISING Rho KINASE INHIBITOR AND PROSTAGLANDINS | SANTEN PHARMACEUTICAL CO LTD (JP) | 2012-02-22 | — | — | EP | disclosed |
| US-20120040994-A1 | THERAPEUTIC AGENT FOR GLAUCOMA COMPRISING Rho KINASE INHIBITOR AND PROSTAGLANDIN | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2012-02-16 | — | — | US | disclosed |
| US-20110263638-A1 | Therapeutic agent for glaucoma comprising rho kinase inhibitor and ß- blocker | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-10-27 | — | — | US | disclosed |
| US-7972612-B2 | Remedy for glaucoma comprising Rho kinase inhibitor and β-blocker | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-07-05 | — | — | US | disclosed |
| EP-2314299-A1 | Therapeutic agent for glaucoma comprising rho kinase inhibitor and prostaglandin | Santen Pharmaceutical Co., Ltd (JP) | 2011-04-27 | — | — | EP | disclosed |
| US-20100063060-A1 | Therapeutic agent for glaucoma comprising Rho Kinhase inhibitor and prostaglandin | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-03-11 | — | — | US | disclosed |
| US-20100041671-A1 | Methods for treating glaucoma | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-02-18 | — | — | US | disclosed |
| US-20060052367-A1 | Remedy for glaucoma comprising rho kinase inhibitor and beta-blocker | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2006-03-09 | — | — | US | disclosed |
| US-20050245509-A1 | Remedy for glaucoma comprising rho kinase inhibitor and prostaglandins | SANTEN PHARMACECUTICAL CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| EP-1568382-A1 | REMEDY FOR GLAUCOMA COMPRISING Rho KINASE INHIBITOR AND &bgr;-BLOCKER | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2005-08-31 | — | — | EP | disclosed |
| EP-1541151-A1 | REMEDY FOR GLAUCOMA COMPRISING Rho KINASE INHIBITOR AND PROSTAGLANDINS | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2005-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260028584-A1 | METHOD FOR EVALUATING AGGREGATION-SUPPRESSING ACTIVITY OR AGGREGATION-PROMOTING ACTIVITY ON AGGREGATING PROTEIN USING ORGANOID, AND METHOD FOR PRODUCING ORGANOID | TTR, IAPP, TPM4 | ROCK2 3149/4885ROCK1 3637/4885CIT 3506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.